NCM
GRCE

Nantahala Capital Management’s Grace Therapeutics GRCE Stock Holding History

Nantahala Capital Management’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-728,203
Closed -$3.37M – 178
2026
Q1 		$3.37M Sell
728,203
-450,000
-38% -$1.77M 0.12% 113
2025
Q4 		$4.08M Hold
1,178,203
– – 0.13% 108
2025
Q3 		$3.51M Hold
1,178,203
– – 0.12% 117
2025
Q2 		$3.5M Hold
1,178,203
– – 0.14% 105
2025
Q1 		$2.69M Buy
+1,178,203
New +$3.71M 0.11% 101

Other funds holding GRCE

Cerity Partners
Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Nantahala Capital Management's GRCE Position: Q2 2026 in Review

Nantahala Capital Management sold out of Grace Therapeutics (GRCE) in Q2 2026, closing a stake of 728,203 shares — an estimated $3.37M sold.

Nantahala Capital Management first reported a position in GRCE in Q1 2025 and held it in 5 quarters. The position peaked at $4.08M in Q4 2025. 33 funds tracked by Wall St. Rank hold GRCE as of Q2 2026.

  • Nantahala Capital Management reported no remaining Grace Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Nantahala Capital Management sold 728,203 Grace Therapeutics shares in Q2 2026, an estimated $3.37M.
  • Nantahala Capital Management first reported a position in Grace Therapeutics in Q1 2025 and held it in 5 quarters.
  • Nantahala Capital Management's Grace Therapeutics position peaked at $4.08M in Q4 2025.
  • 33 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2026.

Based on Nantahala Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.